BNF for Children March 2022 Update

This update contains 4 significant changes, 2 dose changes, and 1 new monograph.

Significant Changes:

• COVID-19: updated guidance.
• COVID-19 vaccines: updated guidance in-line with UK Health Security Agency recommendations.
• Miconazole: oral gel no longer licensed for treatment of intestinal candidiasis.
• Phosphate imbalance: updated guidance on the use of phosphate-binding agents.

Dose Changes:

• Eculizumab [update to children’s dosing].
• Heparin (unfractionated) [dose statement for maintenance of neonatal umbilical arterial catheter amended to reflect use in practice (route removed)].

New monograph:

• Xevudy® [sotrovimab]

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes